Eton begins U.S. commercialization of IMPAVIDO under exclusive rights
Eton Pharmaceuticals ($ETON) launched IMPAVIDO capsules through its U.S. rare-disease commercial organization after obtaining exclusive domestic commercialization rights. The medicine contains miltefosine and treats specified forms of leishmaniasis in eligible adults and adolescents. Distribution is centralized through Anovo Specialty Pharmacy, with outpatient access, hospital consignment and coordination for urgent treatment needs. The launch brings another therapy into Eton’s operating infrast
0